Tuesday, July 17, 2018

Northwestern researchers on a big breakthrough: Slowing cancer cell growth

Monica Ginsburg, reporting for Crain's Chicago Business on 7.12.18, interviews Karl Scheidt, PhD director of the Center for Molecular Innovation and Drug Discovery at Northwestern University. New research led by teams from Northwestern University and Oregon Health & Science University shows that it may be possible to significantly slow down the growth of cancer cells, potentially making them easier to target with existing treatments like chemotherapy and radiation. The study, published in June in the journal Nature Communications, also includes researchers from Xiamen University in China, University of Chicago and the University of Washington. Research funding was provided by the Department of Defense and the Veteran's Administration.
 
Read more in the current issue of Week in Review>> https://conta.cc/2LjgQX7

Monday, June 25, 2018

Study: Herpes Virus May Play Role in Alzheimer's

Jen Christensen, in a June 21, 2018 CNN post, reports that researchers have found strong evidence to suggest that two strains of the human herpes virus -- 6A and 7 -- may contribute to the disease that robs people of their memory and cognitive functions. The research was published Thursday in the journal Neuron. Some scientists have long believed that viruses play a role in the development of Alzheimer's, according to Ms. Christensen. One of the most prominent theories is that Alzheimer's may start in the brain as a response to injury from a virus.
 
Read more in the latest issue of Week in Review>> https://conta.cc/2KjOATK

Tuesday, June 5, 2018

'End of an Era' for Chemo in Non-Small Cell Lung Cancer

Liam Davenport reports for Medscape on June 03, 2018 that most patients with advanced non-small cell lung cancer (NSCLC) can now avoid having chemotherapy as a first-line treatment, after a large, randomized trial showed that immunotherapy with the programmed cell death ligand 1 (PD-L1) blocker pembrolizumab (Keytruda, Merck) is effective even in patients with minimal PD-L1 expression.

Read more in the current issue of Week in Review>> https://conta.cc/2xDXg5G

Wednesday, May 23, 2018

Report Says Changes Will Increase Health Premiums

Premiums for health insurance plans sold on the federal marketplace are expected to increase by nearly 16.9 percent in Florida next year due to changes in the Affordable Care Act, according to a new analysis released Friday <5.18.18>. Released by the Center for American Progress, the analysis estimates that a decision by Congress and President Donald Trump to repeal the mandate that people buy health insurance, coupled with proposed changes to the types of policies that can be sold, will increase premiums for Floridians by $1,011.
 
Read more in the current issue of Week in Review>>

Wednesday, May 9, 2018

Preventing CTE is a no brainer

Chris Nyte, DO, a former nose guard, reminds us of the horrors of chronic traumatic encephalopathy (CTE) in a May 4, 2018 KevinMD post. Clinical findings associated with CTE include memory loss, depression, anxiety, violent behavior, mood disorders and heightened suicidality, the author informs us. It tends to progress with time and can lead to dementia according to a recent study. And the fact that CTE is a direct result of blows to the head such as those suffered by athletes competing in contact sports, especially football, is no longer in doubt.

Read more in the current issue of Week in Review>>

Wednesday, April 25, 2018

A Call for Cost Transparency

Mukul Mehra, MD, in an April 20, 2018 KevinMD post, insists doctors need and want cost transparency. "Physicians are the building blocks of value-based care, yet the cumulative human and financial costs of our decisions are mostly hidden from us," he states.

Read more in the current issue of Week in Review>> https://conta.cc/2FaVKGq 

Wednesday, April 11, 2018

Brilinta or Clopidogrel, Maximum Benefit or Social Responsibility?

An April 7 A Country Doctor Writes blog post illustrates the dilemma faced by American healthcare providers in this examination of the costs and benefits associated with two different prescription medicines used to prevent cardiovascular events.

Read more in the current issue of Week in Review>> https://conta.cc/2IHcGqr